La meningitis es una enfermedad mortal y debilitante; golpea rápidamente, conlleva graves consecuencias sanitarias, económicas y sociales, y afecta a personas de todas las edades y en todos los países del mundo. La
...
meningitis bacteriana puede provocar epidemias, ocasionar la muerte en 24 horas y dejar a una de cada cinco personas afectadas, con discapacidad permanente después de la infección. Muchos casos de meningitis y defunciones conexas son prevenibles mediante vacunación, pero los progresos para derrotar a la meningitis están rezagados respecto de otras enfermedades prevenibles mediante vacunación.
more
The document will provide information for Ministries of Health and hospital sentinel sites on why and how to determine the denominator of at-risk children <5 years of age and rate of meningitis hospitalizations for a sentinel hospital site conductin
...
g IB-VPD surveillance. Such a methodology is currently unavailable and this estimation is critical to enable interpretation of surveillance data, particularly pre- and post- vaccine introduction
more
The meningitis road map has been designated as a flagship global strategy of the WHO’s Thirteenth General Programme of Work, 2019–2023 and is an essential component in achieving universal health coverage.
The road map will reinforce and combi
...
ne with wider initiatives, such as those aimed at strengthening primary health care and health systems, increasing immunization coverage, improving global health security, fighting antimicrobial resistance and advocating for the rights of persons with disabilities. It will complement other global control strategies, such as those addressing sepsis, pneumonia, tuberculosis and HIV. Implementation will be a challenge for all countries across the world, but especially in resource-poor settings where the burden of meningitis is greatest. The targets for the visionary and strategic goals will be adapted to regional and local contexts.
more
WHO Guideline. Since 2010, countries in the meningitis belt have started to introduce a new serogroup A meningococcal conjugate vaccine conferring individual protection and herd immunity. Following the successful roll-out of this vaccine, epidemics
...
due to Neisseria meningitidis serogroup A (NmA) are disappearing, but other serogroups (e.g. NmW, NmX and NmC) still cause epidemics, albeit at a lower frequency and of a smaller size. Due to these changes, WHO organized the review of the evidence to provide recommendations for epidemic control, related to operational thresholds for investigation and response to outbreaks, the use of rapid diagnostic tests, antibiotic regimens in epidemics, and prophylaxis for household contacts of cases
more
Epidemic meningitis is a major public health challenge in the African 'meningitis belt', an area that extends from Senegal to Ethiopia with an estimated total population of 500 million. Since 2002,
...
the World Health Organization (WHO), in collaboration with its collaborating centres for meningitis, has progressively supported countries in implementing a strategy of ES for meningitis. The strategy is the recommended standard for all countries of the Belt and it is now actively being implemented at different levels in all countries.
more
A GUIDE FOR HEALTH WORKERS AND AUTHORITIES IN NIGERIA
WHO practical guidelines. 2nd edition
Report of a WHO technical consultation meeting
Ouagadougou, Burkina Faso
A quick reference guide for health authorities and health-care workers
Revised 2015
Int J Crit Illn Inj Sci. 2012 May-Aug; 2(2): 82–97.
doi: 10.4103/2229-5151.97273
PMCID: PMC3401822
PMID: 22837896
28 Sept. 2021
The focus of this fact sheet is on the four main causes of acute bacterial meningitis:
Neisseria meningitidis (meningococcus)
Streptococcus pneumoniae (pneumococcus)
Haemophilus influenzae
Streptococcus agalacti
...
ae (group B streptococcus)
more
Report for the WHO Meningitis Guideline Revision (May 2014)
Cryptococcal disease is one of the most common opportunistic infections among people living with advanced HIV disease and is a major contributor to severe illness, morbidity, and mortality, particularly in sub-Saharan Africa.
These guidelines update the recommendations that were first released i
...
n 2018 on diagnosing, preventing, and managing cryptococcal disease. In response to important new evidence that became available in 2021, these new guidelines strongly recommend a single high dose of liposomal amphotericin B as part of the preferred induction regimen for the treatment of cryptococcal meningitis in people living with HIV. This simplified regimen - a single high dose of liposomal amphotericin B paired with other standard medicines (flucytosine and fluconazole) - is as effective as the previous WHO standard of care, with the benefits of lower toxicity and fewer monitoring demands.
The objective of these guidelines is to provide updated, evidence-informed recommendations for treating adults, adolescents and children living with HIV who have cryptococcal disease. These guidelines are aimed at HIV programme managers, policymakers, national treatment advisory boards, implementing partners and health-care professionals providing care for people living with HIV in resource-limited settings with a high burden of cryptococcal disease.
more
RBC/IHDPC/ EID Division | November2011 - The aim of the standard operating procedures is to guide health care providers and public health
experts from various levels of the health system in the implementation of enhanced surveillance of meningococcal meni
...
ngitis.
more
Report for WHO Meningitis guideline revision
Dr Thomas Waite, April 2014
Field Epidemiology Services, Public Health England; UK